PRINCETON, N.J., Sept. 4 Medarex, Inc.(Nasdaq: MEDX) announced today that it is scheduled to present at the BearStearns 20th Annual Healthcare Conference at 9:00 AM Eastern Time on Monday,September 10, 2007. The conference is being held at The Grand Hyatt New Yorkin New York City. Medarex's presentation will be webcast live and will beavailable for replay through the Webcast page in the Investor Relationssection of the Medarex website via the Internet at www.medarex.com.
Medarex is a biopharmaceutical company focused on the discovery,development and potential commercialization of fully human antibody-basedtherapeutics to treat life-threatening and debilitating diseases, includingcancer, inflammation, autoimmune disorders and infectious diseases. Medarexapplies its UltiMAb(R) technology and product development and clinicalmanufacturing experience to generate, support and potentially commercialize abroad range of fully human antibody product candidates for itself and itspartners. More than 30 of these therapeutic product candidates derived fromMedarex technology are in human clinical testing or have had INDs submittedfor such trials, with seven of the most advanced product candidates currentlyin Phase III clinical trials. Medarex is committed to building value bydeveloping a diverse pipeline of antibody products to address the world'sunmet healthcare needs. For more information about Medarex, visit its websiteat www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks ofMedarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.